A comparison of CRC screening methods, highlighting fecal DNA methylation’s superior sensitivity in intercepting early, non-bleeding precancers (IMAGE)
Caption
Early detection remains the most effective defense against colorectal cancer (CRC), but not all non-invasive screening modalities offer the same degree of early intervention. A key differentiator lies in detecting advanced precancerous adenomas before malignant transformation and vascular invasion occur.
Here is how three non-invasive screening methods compare:
-
Standard Stool Testing (FIT / gFOBT)
-
Established Carcinoma Sensitivity: 60%–85%
-
Precancerous Sensitivity: 27%–29%
-
Key Considerations: Relies heavily on active bleeding from lesions and requires strict annual compliance, making it prone to patient drop-offs over time.
-
-
cfDNA Liquid Biopsies (Blood Tests)
-
Established Carcinoma Sensitivity: ~80%
-
Precancerous Sensitivity: ~13%
-
Key Considerations: Offers high patient compliance through routine blood draws. However, it misses approximately 87% of advanced precancerous lesions due to minimal circulating tumor DNA shedding at early stages.
-
-
Fecal DNA Methylation Assays
-
Established Carcinoma Sensitivity: High (driven by early molecular detection)
-
Precancerous Sensitivity: ~43%
-
Key Considerations: Directly interrogates exfoliated colonocytes to identify subtle epigenetic alterations prior to vascular invasion. It delivers more than three times the precancerous detection rate of liquid biopsies, identifying lesions before they bleed or become invasive.
-
Credit
BGI Genomics
Usage Restrictions
None
License
Original content